Role of PET/CT in the functional imaging of endocrine pancreatic tumors

Abdominal Imaging

Volumn 37, Issue 6, 2012, Pages 1004-1020

  Rufini, Vittoria ^a   Baum, Richard P ^b,c   Castaldi, Paola ^a   Treglia, Giorgio ^a   De Gaetano, Anna Maria ^a   Carreras, Cecilia ^b,c   Kaemmerer, Daniel ^c,d   Hommann, Merten ^c,d   Hörsch, Dieter ^c,d   Bonomo, Lorenzo ^a   Giordano, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Nuclear Medicine THERANOSTICS Center for Molecular Imaging and Therapy PET/CT Center   (Germany)

^c ENETS Center of Excellence   (Germany)

^d NONE   (Germany)

Author keywords

Endocrine pancreatic tumors; Functional imaging; PET tracers; Positron emission tomography computed tomography (PET CT)

Indexed keywords

5 HYDROXYTRYPTOPHAN C 11; 6 FLUORODOPA F 18; AMINE; CARBIDOPA; CHROMOGRANIN A; DOTA NOC GA 68; DOTA TATE GA 68; DOTA TOC GA 68; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; PANCREAS POLYPEPTIDE; PENTETATE INDIUM IN 111; PEPTIDE HORMONE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GADOLINIUM 1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETATE; GADOTERIC ACID; HETEROCYCLIC COMPOUND; LEVODOPA; ORGANOMETALLIC COMPOUND;

CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DECARBOXYLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOSE RESPONSE; ENDOCRINE TUMOR; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; HYPERINSULINISM; INSULINOMA; KIDNEY CLEARANCE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; URINARY EXCRETION; VON HIPPEL LINDAU DISEASE; WORLD HEALTH ORGANIZATION; CELL DIFFERENTIATION; CLASSIFICATION; METABOLISM; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SCINTISCANNING; SECRETION (PROCESS);

CELL DIFFERENTIATION; CONTRAST MEDIA; DOPAMINE AGENTS; HETEROCYCLIC COMPOUNDS; HUMANS; LEVODOPA; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PEPTIDE HORMONES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84878181590     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-012-9871-9     Document Type: Review

References (72)

1. Oberg K (2010) Pancreatic endocrine tumors. Semin Oncol 37:594-618
2. Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135:1469-1492
3. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511
4. Solcia E, Kloeppel G, Sobin LH (2000) World Health Organization international histological classification of endocrine tumors, 2nd edn. Springer, Berlin
5. Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13-27
6. Öberg K, Castellano D (2011) Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 30(Suppl 1):S3-S7
7. Ekeblad S, Skogseid B, Dunder K, et al. (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798-7803
8. Rindi G, Klöppel G, Alhman H, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395-401
9. Seregni E, Ferrari L, Stivanello M, et al. (2000) Laboratory tests for neuroendocrine tumors. Quart J Nucl Med 44:22-41
10. Lawrence B, Gustafsson BI, Kidd M, et al. (2011) The clinical relevance of Chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab N Am 40:111-134
11. Bombardieri E, Maccauro M, de Deckere E, et al. (2001) Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol 12:51-61
12. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228-247
13. Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825-1835
14. Koopmans KP, Neels ON, Kema IP, et al. (2009) Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol/Hematol 71:199-213
15. Kwekkeboom DJ, Krenning EP (2002) Somatostatin receptor imaging. Semin Nucl Med 32:84-91
16. Basu S, Kumar R, Rubello D, et al. (2008) PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol 33:257-275
17. Khan S, Lloyd C, Szyszko T, et al. (2008) PET imaging in endocrine tumours. Minerva Endocrinol 33:41-52
18. Ambrosini V, Tomassetti P, Franchi R, Fanti S (2010) Imaging of NETs with PET radiopharmaceuticals. Quart J Nucl Med Mol Imaging 54:16-23
19. Miederer M, Weber MM, Fottner C (2010) Molecular imaging of gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin N Am 39:923-935
20. Bombardieri E, Aktolun C, Baum RP, et al. (2003) FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med 30:115-124
21. Boellaard R, O'Doherty MJ, Weber WA, et al. (2010) FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181-200
22. Adams S, Baum R, Rink T, et al. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 25:79-83
23. Ahlström H, Eriksson B, Bergström M, et al. (1995) Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195:333-337
24. 18F- Fluorodihydroxyphenilalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 49:573-586
25. 18F-FDOPA: a multiple target molecule. J Nucl Med 50:1915-1918
26. 18F-fluorodihydroxyphenilalanine in a patient with metastatic carcinoid. J Nucl Med 46:1240-1243
27. 18F-DOPA positron emission tomography. Nuklearmedizin 38:127-130
28. Brown WD, Oakes TR, DeJesus OT, et al. (1998) Fluorine-18-fluoro-l-DOPA dosimetry with carbidopa pretreatment. J Nucl Med 39:1884-1891
29. 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 95(1):303-307
30. 18F]fluoro-l-dopa kinetics in positron emission tomography. J Nucl Med 33:1472-1477
31. 18F-fluoro-l-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48:1599-1606
32. Eriksson B, Örlefors H, Öberg K, et al. (2005) Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab 19:311-324
33. 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90:3392-3400
34. 11C-5-hydroxytryptophan positron emission tomography. J Clin Oncol 26:1489-1495
35. 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 33:60-65
36. Reubi JC (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738
37. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004-2010
38. 68Ga-labeled peptides in tumor imaging. J Nucl Med 46(Suppl 1):172S-178S
39. Hofmann M, Maecke H, Borner H, et al. (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
40. 68Ga- DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 35:72-79
41. Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Quart J Nucl Med Mol Imaging 54:61-67
42. 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1025-1032
43. 68Ga-DOTA-NOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52:886-890
44. 68Ga-DOTAGTOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging 38:2005-2013
45. 18F-DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 220:373-380
46. 18F-DOPA PET. J Nucl Med 45:1161-1167
47. 18F-DOPA positron emission tomography: a diagnostic accuracy study. Lancet Oncol 7:728-734
48. Kauhanen S, Seppanen M, Minn H, Nuutila P (2010) Clinical PET imaging of insulinoma and beta-cell hyperplasia. Curr Pharm Des 16:1550-1560
49. 18F]-DOPA positron emission tomography. Diabetes 55:13-18
50. Kauhanen S, Seppanen M, Nuutila P (2008) Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol 26:5307-5308
51. 68Ga-DOTA- Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518
52. 111In-DTPA-octreotide (Octreoscan). Mol Imaging Biol 13:583-593
53. Baum RP, Prasad V (2008) PET and PET-CT imaging of neuroendocrine tumors. In: Wahl R (ed) Principles and practice of PET and PET/CT. Philadelphia: Lippincott Williams & Wilkins, pp 411-437
54. 68Ga-DOTATOC PET-CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med 39(1):72-82. doi: 10.1007/s00259-011-1935-5
55. Prasad V, Ambrosini V, Hommann M, et al. (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using Ga-68 DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67-77
56. 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumors. Eur Radiol 21:2408-2416
57. Versari A, Camellini L, Carlinfante G, et al. (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors. Clin Nucl Med 35:321-328
58. 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38:1659-1668
59. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71
60. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35:1431-1438
61. 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2031-6
62. 18F-DOPA PET and PET/CT. J Nucl Med 48:1577-1579
63. 18F-DOPA PET/CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 32:575-582
64. Eriksson B, Bergstrom M, Orlefors H, et al. (2000) Use of PET in neuroendocrine tumors. In vivo application and in vitro studies. Quart J Nucl Med 44:68-76
65. 18F-18 fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behaviour? World J Surg 22:588-592
66. Adams S, Baum RP, Hertel A, et al. (1998) Metabolic (PET) and receptor (SPET) imaging of well and less well differentiated tumors: comparison with expression of the Ki-67 antigen. Nucl Med Commun 19:641-647
67. Baum RP, Prasad V, Hommann M, Hörsch D (2008) Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 170:225-242
68. 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858-864
69. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025-2033
70. Wild D, Macke H, Christ E, Gloor B, Reubi JC (2008) Glucagon-like peptide-1 receptor scans to localize occult insulinomas. N Engl J Med 359:766-768
71. Christ E, Wild D, Forrer F, et al. (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398-4405
72. Wild D, Christ E, Caplin ME, et al. (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 52:1073-1078